Currently out of the existing stock ratings of Adam Walsh, 61 are a BUY (89.71%), 7 are a HOLD (10.29%).

Adam Walsh

Work Performance Price Targets & Ratings Chart

Analyst Adam Walsh, currently employed carries an average stock price target met ratio of 67% that have a potential upside of 39.91% achieved within 208 days. Previously, Adam Walsh worked at STIFEL.

Adam Walsh’s has documented 132 price targets and ratings displayed on 15 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on GLPG, Galapagos NV ADR at 10-Jul-2020.

Wall Street Analyst Adam Walsh

Analyst best performing recommendations are on VRTX (VERTEX PHARMACEUTICALS).
The best stock recommendation documented was for VRTX (VERTEX PHARMACEUTICALS) at 7/18/2017. The price target of $154 was fulfilled within 1 day with a profit of $21.84 (16.53%) receiving and performance score of 165.25.

Average potential price target upside

of $25.02 (24.78%) on ASND (ASCENDIS PHARMA AS).
of $24.19 (43.54%) on RETA (REATA PHARMACEUTICALS).
of $24.17 (23.39%) on VRTX (VERTEX PHARMACEUTICALS).

CNCE Concert Pharmaceuticals CORT Corcept Therapeutics orporated INSM Insmed DRRX Durect RARE Ultragenyx ALDX Aldeyra The PHAS PhaseBio Pharmaceuticals VRTX Vertex Pharmaceuticals GLPG Galapagos NV ADR RETA Reata Pharmaceuticals ASND Ascendis Pharma AS FGEN FibroGen GLMD Galmed Pharmaceuticals Ltd PTGX Protagonist Therapeutics SAGE Sage Therapeutic

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Stephen Kim (EVERCORE)